Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon and Ribavirin in Thalassemia and Sickle Cell Patients with Hepatitis C
NCT00887081Phase 4Unknown
- Sponsor
- ARNAS Villa Sofia-Cervello
- Start
- Jan 2009
- Primary completion
- Dec 2013
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in hepatitis C virus infection, sponsored by ARNAS Villa Sofia-Cervello. Status: unknown.
02
Drugs
peginterferon alfa-2apeginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00887081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887081.